Severe Epistaxis with Tyrosine Kinase Inhibitors

Clinical Oncology

Volumn 20, Issue 4, 2008, Pages 318-319

  Hall, P S ^a   Kancherla, K ^a   Sastry, P S R K ^a   Brown, J E ^a  

^a ST JAMES S INSTITUTE OF ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; SUNITINIB;

ADULT; CANCER RECURRENCE; CASE REPORT; CAUTERIZATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FLUID RESUSCITATION; HOSPITAL ADMISSION; HUMAN; KIDNEY CARCINOMA; LETTER; LIVER METASTASIS; MALE; PANCREAS CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; UNINEPHRECTOMY;

CARCINOMA, RENAL CELL; EPISTAXIS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES;

EID: 41449099279     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.02.001     Document Type: Letter

References (7)

1. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
2. Demetri G., vanOsterom A., Garrett R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
3. Pfizer. Manufacturer product information on Sutent, 2007.
4. Bayer. Prescribing information. Available from:. http://www.nexavar.com/wt/page/index
5. Kamba T., and McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 (2007) 1788-1795
6. Osusky K., Hallahan D., Fu A., et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumour vessels. Angiogenesis 7 (2004) 225-233
7. Vinogradov M., Moualla H., Liles D.K., et al. Acquired factor VIII inhibitor in a patient treated with sunitinib. J Immunother 29 (2006) 674